Merck posts losses tied to troubled blood-thinner
February 03, 2011 at 09:17 AM EST
Research for blood-thinning treatment results in $530 million loss, and financial outlook for the year is lower than expected, hitting the stock price.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.